| Host |
Mouse |
| Klon |
QBend/10 |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:100 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cell Membrane |
CD34
|
Diagnostic Biosystems |
QBend/10 |
0.1 ml |
Concentrate |
CE/IVD |
MOB098-01 |
-
|
| Host |
Mouse |
| Klon |
QBend/10 |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:100 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cell Membrane |
CD34
|
Diagnostic Biosystems |
QBend/10 |
0.5 ml |
Concentrate |
CE/IVD |
MOB098-05 |
-
|
| Host |
Mouse |
| Klon |
QBend/10 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cell Membrane |
CD34
|
Diagnostic Biosystems |
QBend/10 |
6 ml |
Ready-to-use |
CE/IVD |
PDM050 |
-
|
| Host |
Mouse |
| Klon |
QBEnd-10 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Hemangioma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Detergent solubilized vesicular suspension prepared from a perfusate of human term placenta |
| Lokalisation |
Cell membrane/Cytoplasm |
CD34
|
Zeta Corporation |
QBEnd-10 |
1.0 ml |
Concentrate |
CE/IVD |
Z2063ML |
-
|
| Host |
Mouse |
| Klon |
QBEnd-10 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Hemangioma. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Detergent solubilized vesicular suspension prepared from a perfusate of human term placenta |
| Lokalisation |
Cell membrane/Cytoplasm |
CD34
|
Zeta Corporation |
QBEnd-10 |
7 ml |
Ready-to-use |
CE/IVD |
Z2063MP |
-
|
| Host |
Mouse |
| Klon |
QBEnd-10 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Hemangioma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Detergent solubilized vesicular suspension prepared from a perfusate of human term placenta |
| Lokalisation |
Cell membrane/Cytoplasm |
CD34
|
Zeta Corporation |
QBEnd-10 |
0.5 ml |
Concentrate |
CE/IVD |
Z2063MS |
-
|
| Host |
Mouse |
| Klon |
QBEnd-10 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Hemangioma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Detergent solubilized vesicular suspension prepared from a perfusate of human term placenta |
| Lokalisation |
Cell membrane/Cytoplasm |
CD34
|
Zeta Corporation |
QBEnd-10 |
0.1 ml |
Concentrate |
CE/IVD |
Z2063MT |
-
|
| Host |
Rat |
| Klon |
MEC14.7 |
| Format |
Purified |
| Methode |
IP, FL |
| Isotyp |
Rat IgG2a |
CD34 (Endothelial Cell) (Low Endotoxin)
|
Zytomed Systems GmbH |
MEC14.7 |
500 µg |
Purified |
RUO |
603-0832 |
-
|
| Host |
Mouse |
| Klon |
QBEND/10 |
| Format |
Purified |
| Methode |
FL |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Human endothelial cell membrane vesicles |
CD34 (Endothelial Cell) - FITC
|
Zytomed Systems GmbH |
QBEND/10 |
100 Tests |
Purified |
RUO |
603-0845C |
-
|
| Host |
Rabbit |
| Klon |
SP191 |
| Methode |
IHC-P |
| Verdünnung |
1:100 |
CD35
|
Zytomed Systems GmbH |
SP191 |
1 ml |
- |
RUO |
503-4914 |
-
|
| Host |
Mouse |
| Klon |
E11 |
| Format |
Purified |
| Methode |
F, P, WB, FL |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Human Tonsil |
| Verdünnung |
1-10 µg/mL (P) |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Human acute monocytic leukemia cells |
CD35 (CR1)
|
Zytomed Systems GmbH |
E11 |
100 µg |
Purified |
RUO |
603-0851 |
-
|
| Host |
Rabbit |
| Klon |
SP149 |
| Format |
Concentrate |
| Methode |
P, FL |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to the C-terminus of human CD38 protein. |
| Lokalisation |
Cell membrane |
CD38
|
Zytomed Systems GmbH |
SP149 |
0.1 ml |
Concentrate |
RUO |
503-4490 |
-
|
| Host |
Rabbit |
| Klon |
SP149 |
| Format |
Concentrate |
| Methode |
P, FL |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to the C-terminus of human CD38 protein. |
| Lokalisation |
Cell membrane |
CD38
|
Zytomed Systems GmbH |
SP149 |
0.5 ml |
Concentrate |
RUO |
503-4492 |
-
|
| Host |
Rabbit |
| Klon |
SP149 |
| Format |
Concentrate |
| Methode |
P, FL |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to the C-terminus of human CD38 protein. |
| Lokalisation |
Cell membrane |
CD38
|
Zytomed Systems GmbH |
SP149 |
1 ml |
Concentrate |
RUO |
503-4494 |
-
|
| Host |
Rabbit |
| Klon |
ZR351 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Peptide derived from the C-terminus of human CD38 protein |
| Lokalisation |
Cytoplasm |
CD38
|
Zeta Corporation |
ZR351 |
1 ml |
Concentrate |
CE/IVD |
Z2610RL |
-
|
| Host |
Rabbit |
| Klon |
ZR351 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Peptide derived from the C-terminus of human CD38 protein |
| Lokalisation |
Cytoplasm |
CD38
|
Zeta Corporation |
ZR351 |
7 ml |
Ready-to-use |
CE/IVD |
Z2610RP |
-
|
| Host |
Rabbit |
| Klon |
ZR351 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Peptide derived from the C-terminus of human CD38 protein |
| Lokalisation |
Cytoplasm |
CD38
|
Zeta Corporation |
ZR351 |
0.5 ml |
Concentrate |
CE/IVD |
Z2610RS |
-
|
| Host |
Rabbit |
| Klon |
ZR351 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Peptide derived from the C-terminus of human CD38 protein |
| Lokalisation |
Cytoplasm |
CD38
|
Zeta Corporation |
ZR351 |
0.1 ml |
Concentrate |
CE/IVD |
Z2610RT |
-
|
| Host |
Mouse |
| Klon |
AT13/5 |
| Format |
Purified |
| Methode |
F, IP, FL |
| Isotyp |
Mouse IgG1 |
CD38 (Azide Free)
|
Zytomed Systems GmbH |
AT13/5 |
1 mg |
Purified |
RUO |
603-0870F |
-
|
| Host |
Mouse |
| Klon |
GRP-P |
| Format |
Lyophilised |
| Methode |
FL |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Human red blood cells and platelets |
CD42a - RPE
|
Zytomed Systems GmbH |
GRP-P |
100 Tests |
Lyophilised |
RUO |
603-0925E |
-
|
| Host |
Rabbit |
| Klon |
SP202 |
| Format |
Concentrate |
| Reaktivität |
MS |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Bone Marrow, Spleen |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide from human CD42b protein |
| Lokalisation |
Cell Membrane |
CD42b
|
Zytomed Systems GmbH |
SP202 |
0.1 ml |
Concentrate |
RUO |
503-5020 |
-
|
| Host |
Rabbit |
| Klon |
SP202 |
| Format |
Concentrate |
| Reaktivität |
MS |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Bone Marrow, Spleen |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide from human CD42b protein |
| Lokalisation |
Cell Membrane |
CD42b
|
Zytomed Systems GmbH |
SP202 |
0.5 ml |
Concentrate |
RUO |
503-5022 |
-
|
| Host |
Rabbit |
| Klon |
SP202 |
| Format |
Concentrate |
| Reaktivität |
MS |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Bone Marrow, Spleen |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide from human CD42b protein |
| Lokalisation |
Cell Membrane |
CD42b
|
Zytomed Systems GmbH |
SP202 |
1 ml |
Concentrate |
RUO |
503-5024 |
-
|
| Host |
Mouse |
| Klon |
DF-T1 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate (optional) |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1 kappa |
| Verdünnung |
Pluripotent human cell line K562 |
| Lokalisation |
Cell Membrane |
CD43
|
Zytomed Systems GmbH |
DF-T1 |
1 ml |
Concentrate |
RUO |
MSK065 |
-
|
| Host |
Mouse |
| Klon |
DF-T1 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate (optional) |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1 kappa |
| Verdünnung |
Pluripotent human cell line K562 |
| Lokalisation |
Cell Membrane |
CD43
|
Zytomed Systems GmbH |
DF-T1 |
0.5 ml |
Concentrate |
RUO |
MSK065-05 |
-
|
| Host |
Mouse |
| Klon |
DF-T1 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil, CLL/SLL, or lymph node. |
| Verdünnung |
1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Stimulated human leukocytes |
| Lokalisation |
Cell membrane |
CD43
|
Zeta Corporation |
DF-T1 |
1.0 ml |
Concentrate |
CE/IVD |
Z2032ML |
-
|
| Host |
Mouse |
| Klon |
DF-T1 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil, CLL/SLL, or lymph node. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Stimulated human leukocytes |
| Lokalisation |
Cell membrane |
CD43
|
Zeta Corporation |
DF-T1 |
7 ml |
Ready-to-use |
CE/IVD |
Z2032MP |
-
|
| Host |
Mouse |
| Klon |
DF-T1 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil, CLL/SLL, or lymph node. |
| Verdünnung |
1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Stimulated human leukocytes |
| Lokalisation |
Cell membrane |
CD43
|
Zeta Corporation |
DF-T1 |
0.5 ml |
Concentrate |
CE/IVD |
Z2032MS |
-
|
| Host |
Mouse |
| Klon |
DF-T1 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil, CLL/SLL, or lymph node. |
| Verdünnung |
1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Stimulated human leukocytes |
| Lokalisation |
Cell membrane |
CD43
|
Zeta Corporation |
DF-T1 |
0.1 ml |
Concentrate |
CE/IVD |
Z2032MT |
-
|
| Host |
Mouse |
| Klon |
156-3C11 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Diva modified Citrate pH 6.2 |
| Positivkontrolle |
Tonsil, breast cancer |
| Verdünnung |
1:150 - 1:300 |
| Isotyp |
Mouse IgG2a |
| Lokalisation |
Cell membrane, cytoplasmic |
CD44
|
Biocare Medical |
156-3C11 |
0.1 ml |
Concentrate |
CE/IVD |
CM318A |
-
|
| Host |
Mouse |
| Klon |
156-3C11 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Diva modified Citrate pH 6.2 |
| Positivkontrolle |
Tonsil, breast cancer |
| Verdünnung |
1:150 - 1:300 |
| Isotyp |
Mouse IgG2a |
| Lokalisation |
Cell membrane, cytoplasmic |
CD44
|
Biocare Medical |
156-3C11 |
0.5 ml |
Concentrate |
CE/IVD |
CM318B |
-
|
| Host |
Mouse |
| Klon |
156-3C11 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:75 |
| Isotyp |
Mouse IgG2a |
| Lokalisation |
Cell Membrane |
CD44
|
Diagnostic Biosystems |
156-3C11 |
1 ml |
Concentrate |
CE/IVD |
MOB256 |
-
|
| Host |
Mouse |
| Klon |
156-3C11 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:75 |
| Isotyp |
Mouse IgG2a |
| Lokalisation |
Cell Membrane |
CD44
|
Diagnostic Biosystems |
156-3C11 |
0.1 ml |
Concentrate |
CE/IVD |
MOB256-01 |
-
|
| Host |
Mouse |
| Klon |
156-3C11 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:75 |
| Isotyp |
Mouse IgG2a |
| Lokalisation |
Cell Membrane |
CD44
|
Diagnostic Biosystems |
156-3C11 |
0.5 ml |
Concentrate |
CE/IVD |
MOB256-05 |
-
|
| Host |
Mouse |
| Klon |
156-3C11 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Mouse IgG2a |
| Lokalisation |
Cell Membrane |
CD44
|
Diagnostic Biosystems |
156-3C11 |
6 ml |
Ready-to-use |
CE/IVD |
PDM172 |
-
|
| Host |
Mouse |
| Klon |
156-3C11 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Diva modified Citrate pH 6.2 |
| Positivkontrolle |
Tonsil, breast cancer |
| Verdünnung |
- |
| Isotyp |
Mouse IgG2a |
| Lokalisation |
Cell membrane, cytoplasmic |
CD44
|
Biocare Medical |
156-3C11 |
6 ml |
Ready-to-use |
CE/IVD |
PM318AA |
-
|
| Host |
Mouse |
| Klon |
VFF-7 |
| Format |
Purified |
| Methode |
F, P, WB, FL |
| Vorbehandlung |
Citrate |
| Verdünnung |
1:200 (P) |
| Isotyp |
Mouse IgG1 |
CD44v6
|
Zytomed Systems GmbH |
VFF-7 |
100 µg |
Purified |
RUO |
603-0983 |
-
|
| Host |
Mouse |
| Klon |
VFF-7 |
| Format |
Purified |
| Methode |
FL |
| Isotyp |
Mouse IgG1 |
CD44v6 - FITC
|
Zytomed Systems GmbH |
VFF-7 |
100 Tests |
Purified |
RUO |
603-0985C |
-
|
| Host |
Rat |
| Klon |
YW62.3 |
| Format |
Purified |
| Methode |
F, IP, FL |
| Isotyp |
Rat IgG2b |
| Verdünnung |
Mouse spleen cells |
CD45 (LCA)
|
Zytomed Systems GmbH |
YW62.3 |
100 µg |
Purified |
RUO |
603-0993 |
-
|
| Host |
Rabbit |
| Klon |
ZR361 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil or lymph node |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length human PTPRC protein |
| Lokalisation |
Cell surface and cytoplasm |
CD45 (LCA)
|
Zeta Corporation |
ZR361 |
1 ml |
Concentrate |
CE/IVD |
Z2737RL |
-
|
| Host |
Rabbit |
| Klon |
ZR361 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil or lymph node |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length human PTPRC protein |
| Lokalisation |
Cell surface and cytoplasm |
CD45 (LCA)
|
Zeta Corporation |
ZR361 |
7 ml |
Concentrate |
CE/IVD |
Z2737RP |
-
|
| Host |
Rabbit |
| Klon |
ZR361 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil or lymph node |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length human PTPRC protein |
| Lokalisation |
Cell surface and cytoplasm |
CD45 (LCA)
|
Zeta Corporation |
ZR361 |
0.5 ml |
Concentrate |
CE/IVD |
Z2737RS |
-
|
| Host |
Rabbit |
| Klon |
ZR361 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil or lymph node |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length human PTPRC protein |
| Lokalisation |
Cell surface and cytoplasm |
CD45 (LCA)
|
Zeta Corporation |
ZR361 |
0.1 ml |
Concentrate |
CE/IVD |
Z2737RT |
-
|
| Host |
Rabbit |
| Klon |
ZR118 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length human PTPRC protein |
| Lokalisation |
Cell surface and cytoplasmic |
CD45RA
|
Zeta Corporation |
ZR118 |
1 ml |
Concentrate |
CE/IVD |
Z2681RL |
-
|
| Host |
Rabbit |
| Klon |
ZR118 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length human PTPRC protein |
| Lokalisation |
Cell surface and cytoplasmic |
CD45RA
|
Zeta Corporation |
ZR118 |
7 ml |
Concentrate |
CE/IVD |
Z2681RP |
-
|
| Host |
Rabbit |
| Klon |
ZR118 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length human PTPRC protein |
| Lokalisation |
Cell surface and cytoplasmic |
CD45RA
|
Zeta Corporation |
ZR118 |
0.5 ml |
Concentrate |
CE/IVD |
Z2681RS |
-
|
| Host |
Rabbit |
| Klon |
ZR118 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length human PTPRC protein |
| Lokalisation |
Cell surface and cytoplasmic |
CD45RA
|
Zeta Corporation |
ZR118 |
0.1 ml |
Concentrate |
CE/IVD |
Z2681RT |
-
|
| Host |
Mouse |
| Klon |
2B11/PD7-26 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil or lymph node. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ + IgG1 /κ |
| Verdünnung |
PD7/26/16: human peripheral blood lymphocytes maintained in T cell growth factor. 2B11: isolated neoplastic cells from T cell lymphoma |
| Lokalisation |
Cell membrane |
CD45RB (LCA)
|
Zeta Corporation |
2B11/PD7-26 |
1.0 ml |
Concentrate |
CE/IVD |
Z2093ML |
-
|
| Host |
Mouse |
| Klon |
2B11/PD7-26 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil or lymph node. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ + IgG1 /κ |
| Verdünnung |
PD7/26/16: human peripheral blood lymphocytes maintained in T cell growth factor. 2B11: isolated neoplastic cells from T cell lymphoma |
| Lokalisation |
Cell membrane |
CD45RB (LCA)
|
Zeta Corporation |
2B11/PD7-26 |
7 ml |
Ready-to-use |
CE/IVD |
Z2093MP |
-
|
| Host |
Mouse |
| Klon |
2B11/PD7-26 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil or lymph node. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ + IgG1 /κ |
| Verdünnung |
PD7/26/16: human peripheral blood lymphocytes maintained in T cell growth factor. 2B11: isolated neoplastic cells from T cell lymphoma |
| Lokalisation |
Cell membrane |
CD45RB (LCA)
|
Zeta Corporation |
2B11/PD7-26 |
0.5 ml |
Concentrate |
CE/IVD |
Z2093MS |
-
|